FFA
MYGN icon

Farther Finance Advisors’s Myriad Genetics MYGN Stock Holding History

Farther Finance Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6.02K Buy
1,396
+218
+19% +$919 ﹤0.01% 4904
2026
Q2 		$6.79K Buy
1,178
+676
+135% +$3.07K ﹤0.01% 4630
2026
Q1 		$2.3K Sell
502
-248
-33% -$1.29K ﹤0.01% 4847
2025
Q4 		$4.61K Sell
750
-2,233
-75% -$16.2K ﹤0.01% 4355
2025
Q3 		$21.6K Sell
2,983
-2,366
-44% -$14K ﹤0.01% 2996
2025
Q2 		$28.4K Buy
5,349
+5,264
+6,193% +$31.1K ﹤0.01% 2453
2025
Q1 		$751 Sell
85
-27
-24% -$324 ﹤0.01% 3696
2024
Q4 		$1.54K Sell
112
-89
-44% -$1.64K ﹤0.01% 3108
2024
Q3 		$5.5K Buy
201
+9
+5% +$244 ﹤0.01% 2599
2024
Q2 		$4.6K Sell
192
-68
-26% -$1.49K ﹤0.01% 2431
2024
Q1 		$5.57K Buy
260
+226
+665% +$4.86K ﹤0.01% 2019
2023
Q4 		$651 Buy
34
+19
+127% +$329 ﹤0.01% 2884
2023
Q3 		$241 Sell
15
-199
-93% -$3.79K ﹤0.01% 2435
2023
Q2 		$4.96K Hold
214
– – ﹤0.01% 1437
2023
Q1 		$4.97K Buy
214
+199
+1,327% +$4.04K ﹤0.01% 1342
2022
Q4 		$218 Buy
+15
New +$279 ﹤0.01% 2027

Other funds holding MYGN

WN
Williams & Novak Westlake Village, California $169M AUM 17.63% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors's MYGN Position: Q3 2026 in Review

Farther Finance Advisors increased its Myriad Genetics (MYGN) stake by 19% in Q3 2026, buying an estimated $919 and bringing the position to 1,396 shares worth $6.02K. The position accounts for ﹤0.01% of the portfolio, ranked #4904.

Farther Finance Advisors first reported a position in MYGN in Q4 2022 and has held it in 16 quarters since. The position peaked at $28.4K in Q2 2025. 3 funds tracked by Wall St. Rank hold MYGN as of Q3 2026.

  • Farther Finance Advisors held 1,396 shares of Myriad Genetics worth $6.02K as of Q3 2026.
  • Farther Finance Advisors bought 218 Myriad Genetics shares in Q3 2026, an estimated $919.
  • Myriad Genetics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #4904 holding.
  • Farther Finance Advisors first reported a position in Myriad Genetics in Q4 2022 and has held it in 16 quarters since.
  • Farther Finance Advisors's Myriad Genetics position peaked at $28.4K in Q2 2025.
  • 3 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.